Does Benzene Cause Acute Myeloid Leukemia?

From General Health to Occupational Concern

For decades, general health and science information has served as a foundational resource for public understanding of disease prevention and environmental risks. Within this broad context, discussions of chemical exposures have typically focused on lifestyle factors, such as smoking or diet, as primary contributors to chronic illness. This legacy framework has provided valuable guidance for reducing harm from well-known hazards. However, as occupational health research has matured, attention has increasingly turned to specific industrial settings where exposure levels can be far higher and more sustained than in everyday life. In particular, the manufacturing and processing of chemicals in mass production environments introduces distinct risk profiles that differ markedly from general population exposures. This shift in focus requires moving beyond broad health advice to examine how routine workplace contact with certain substances may influence disease development over time. One substance that has drawn significant scrutiny in this regard is benzene, a common industrial solvent and component of crude oil. The transition from general health awareness to occupational concern centers on whether prolonged benzene exposure in factory settings is linked to the development of acute myeloid leukemia, a serious blood cancer. This question represents a critical intersection of public health knowledge and industrial hygiene, demanding careful consideration of exposure patterns distinct from those addressed in traditional health education.

Benzene as a Known Carcinogen

Benzene is a well-established myelotoxin and recognized human carcinogen. Chronic exposure to benzene has been linked to an increased risk of developing acute myeloid leukemia (AML), a hematologic malignancy characterized by the rapid proliferation of abnormal myeloid progenitor cells in the bone marrow and peripheral blood. The clinical presentation of AML typically includes symptoms related to bone marrow failure, such as fatigue, pallor, infection, and bleeding, along with signs of extramedullary involvement. Diagnosis is confirmed through bone marrow aspiration and biopsy, demonstrating at least 20% blasts in the marrow or blood, with immunophenotyping and cytogenetic analysis used to classify subtypes and guide treatment. Benzene is metabolized in the liver and bone marrow to reactive intermediates, including benzene oxide, phenol, and hydroquinone, which can cause direct DNA damage and chromosomal aberrations. The carcinogenic ability of benzene has been reported, and chronic exposure to benzene can be one of the risk elements for solid cancers and hematological neoplasms (https://pubmed.ncbi.nlm.nih.gov/34069279/). Possible mechanisms of benzene initiation of hematological tumors include a genotoxic effect, an action on oxidative stress and inflammation, and the provocation of immunosuppression (https://pubmed.ncbi.nlm.nih.gov/34069279/). However, it is becoming evident that genetic alterations and other causes are insufficient to fully justify several phenomena that influence the onset of hematologic malignancies (https://pubmed.ncbi.nlm.nih.gov/34069279/). Epigenetic effects, such as altered gene expression, are also implicated in benzene-induced leukemogenesis.

Occupational Exposure and Risk Evidence

Occupational exposure to benzene at levels of 10 ppm or more has been associated with increased risk of AML (https://pubmed.ncbi.nlm.nih.gov/33429013/). The mode of action for AML development leading to mortality is anticipated to include multiple earlier key events, which can be observed in hematotoxicity and genetic toxicity in peripheral blood of exposed workers (https://pubmed.ncbi.nlm.nih.gov/33429013/). Prevention of these early events would lead to prevention of the apical adverse outcomes, the morbidity and mortality caused by myelodysplastic syndromes and AML (https://pubmed.ncbi.nlm.nih.gov/33429013/). Incorporation of key event information should modify the risk model, but few modification approaches have been suggested (https://pubmed.ncbi.nlm.nih.gov/33429013/). Epidemiological evidence supports a causal relationship between benzene exposure and AML. In a meta-analysis of childhood cancers, benzene exposure was associated with an increased risk of AML (odds ratio [OR]: 1.22, 95% confidence interval [CI]: 1.02-1.46; 4 studies; I2 = 0.0%) (https://pubmed.ncbi.nlm.nih.gov/41485753/). This finding was based on studies of ambient air pollution, with results presented per 1 μg/m³ increase in benzene exposure (https://pubmed.ncbi.nlm.nih.gov/41485753/). In a national cohort from Switzerland, occupational exposure to benzene was found to be associated with elevated mortality risks for AML, diffuse large B-cell lymphoma, and possibly follicular lymphoma (https://pubmed.ncbi.nlm.nih.gov/38727681/). Previous studies established a causal relationship between occupational benzene exposure and AML (https://pubmed.ncbi.nlm.nih.gov/38727681/). However, mixed results have been reported for associations between benzene exposure and other myeloid and lymphoid malignancies (https://pubmed.ncbi.nlm.nih.gov/38727681/).

Latency, Dose-Response, and Warnings

The timeline between benzene exposure and documented harm can vary. For AML, latency periods of several years to decades are typical after initial exposure. The risk appears to increase with cumulative exposure and duration. Early hematotoxic effects, such as decreased blood cell counts, may precede the development of AML by months or years. These early key events serve as biomarkers of exposure and potential risk. Regarding adequacy of warnings, regulatory agencies and occupational safety organizations have established permissible exposure limits for benzene, such as the Occupational Safety and Health Administration (OSHA) permissible exposure limit of 1 ppm over an 8-hour workday. However, the evidence suggests that even lower levels of exposure may confer risk. The meta-analysis of childhood cancers found an increased risk of AML associated with benzene exposure at ambient levels (https://pubmed.ncbi.nlm.nih.gov/41485753/). This raises questions about whether current warnings adequately communicate the potential for harm at lower exposure levels, particularly for vulnerable populations such as children. For affected patients, causation-related considerations include the strength of the association, dose-response relationship, and temporal sequence. The evidence demonstrates a consistent association between benzene exposure and AML, with a plausible biological mechanism. The dose-response relationship is supported by occupational studies showing increased risk at higher exposure levels. The temporal sequence is established by the latency period between exposure and disease onset. However, individual cases may involve multiple risk factors, and benzene exposure may not be the sole cause. Patients with a history of benzene exposure and a diagnosis of AML should be evaluated for potential occupational or environmental sources of exposure. In summary, benzene is a known cause of AML, with evidence from mechanistic, occupational, and epidemiological studies. The risk is dose-dependent, and early hematotoxic effects can precede disease onset. Adequacy of warnings should be considered in light of evidence for risk at lower exposure levels. For affected patients, causation is supported by the strength of the association, biological plausibility, and temporal relationship.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the link between benzene and acute myeloid leukemia?

Benzene is a known human carcinogen that can cause acute myeloid leukemia (AML). Chronic exposure to benzene, especially in occupational settings, increases the risk of developing AML through mechanisms including DNA damage, oxidative stress, and epigenetic changes. Epidemiological studies consistently show a causal relationship, with higher exposure levels associated with greater risk.

How long does it take for benzene exposure to cause leukemia?

The latency period between benzene exposure and the development of AML typically ranges from several years to decades. Early hematotoxic effects, such as decreased blood cell counts, may appear months to years before AML diagnosis. The risk increases with cumulative exposure and duration of exposure.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Benzene exposure and a confirmed Acute Myeloid Leukemia diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.